Characteristic | No. patients (%) |
---|---|
Age, y | Â |
   >= 60 | 26 (26.5) |
   <60 | 72 (73.5) |
Sex | Â |
   Male | 73 (74.5) |
   Female | 25 (25.5) |
T-classification at initial diagnosis | Â |
   T1 | 19 (19.4) |
   T2 | 30 (30.6) |
   T3 | 42 (42.9) |
   T4 | 7 (7.1) |
AJCC staging group at initial diagnosis | Â |
   I | 11 (11.2) |
   II | 24 (24.5) |
   III | 18 (18.4) |
   IV | 45 (45.9) |
Fuhrman grade | Â |
   1 | 4 (4.1) |
   2 | 49 (50.0) |
   3 | 39 (39.8) |
   4 | 6 (6.1) |
Histology | Â |
   Predominant clear cell | 87 (88.8) |
   Non-clear cell | 11 (11.2) |
Sites of metastatic diseases | Â |
   Lung | 70 (71.4) |
   Liver | 10 (10.2) |
   Bone | 18 (18.4) |
   Lymph node | 24 (24.5) |
   Adrenal gland | 12 (12.2) |
   Other | 12 (12.2) |
Number of metastatic foci | Â |
   1 | 20 (20.4) |
   2 | 29 (29.6) |
   3 | 21 (21.4) |
   >= 4 | 28 (28.6) |
ECOG performance status | Â |
   0 | 56 (57.1) |
   1 | 37 (37.8) |
   2 | 4 (4.1) |
   3 | 1 (1.0) |